Accurexa to Present at 2015 Stem Cell Meeting on the Mesa

NEWARK, DE / ACCESSWIRE / September 28, 2015 / Accurexa Inc. (the “Company”) (OTCQB: ACXA), a biotechnology company focused on the development of novel neurological therapies to be directly delivered into the brain, announced today that George Yu, MD, President & CEO, will present at the annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California.

This conference is the sector’s premiere forum bringing together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures.

Co-hosted by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2015 Stem Cell Meeting on the Mesa is a three-day conference featuring program’s two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.

At the Partnering Forum, held October 7 and 8, industry executives will lead in-depth, interactive panels and workshops to discuss critical commercial issues facing the sector today.

The nationally recognized Scientific Symposium, held October 9 at the Salk Institute for Biological Studies, will showcase leading academic research in the field of regenerative medicine and advanced therapies.

Stem Cell Meeting on the Mesa is expected to attract nearly 800 attendees, including leading cell therapy, gene therapy and tissue engineering companies, large pharma and biotech, industry investors and major academic research institutions.

The following are specific details regarding Accurexa’s presentation at the conference:

Event: 2015 Stem Cell Meeting on the Mesa – Partnering Forum

Date: Wednesday, October 7, 2015

Time: 1:15pm Pacific Standard Time

Location: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037

A live video webcast of all company presentations will be available at: http://stemcellmeetingonthemesa.com/webcast/ and will also be published on ARM’s website shortly after the event.

Please visit http://stemcellmeetingonthemesa.com/ for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Parsons at lparsons@alliancerm.org and interested media should contact Lyndsey Scull at lscull@alliancerm.org.

About Accurexa, Inc.

The Company is focused on developing novel neurological therapies to be directly delivered into specific regions of the brain. The company is developing its ACX-31 program to deliver two chemotherapy drugs, temozolomide in combination with BCNU, locally to brain tumor sites. The ACX-31 program is based on an issued patent licensed from Accelerating Combination Therapies LLC which is co-owned by Dr. Henry Brem, Director of the Neurosurgery Department at Johns Hopkins University. The Company is collaborating in the development of its ACX-31 program with Dr. Henry Brem who built one of the largest brain tumor research and treatment centers in the world at Johns Hopkins University. Dr. Robert Langer, who is the David H. Koch Institute Professor at MIT and the most cited engineer in history, is also advising the Company in the development of its ACX-31 program. Both Dr. Brem and Dr. Langer are pioneers in the development of local drug delivery treatments, and invented and developed Gliadel(R) which is a FDA approved, local chemotherapy for the treatment of glioblastoma multiforme.

Oral temozolomide is a generic, FDA approved, first-line chemotherapy drug that is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. Before oral temozolomide became generic, it generated US sales of $420 million and global sales of $910 million under its brand name Temodar in 2012. However, current standard of care of delivering temozolomide to tumor sites through oral administration is limited by the blood-brain-barrier and oral temozolomide increases patient survival by 2.5 months from a 12.1 months median overall survival.

Animal studies at the Johns Hopkins School of Medicine(1) have shown that local delivery of temozolomide increased concentrations of the drug in the brain threefold and increased survival up to fourfold compared with oral administration. The percentage of long-term survivors for groups receiving local delivery of temozolomide ranged from 25% to 37.5% while there were no long-term survivors with orally administered temozolomide. Further animal studies at the Johns Hopkins School of Medicine(2) have shown that the additive effect of combined delivery of local temozolomide with local BCNU, especially in combination with radiotherapy, was significantly more effective than delivery of either drug alone or one systemically and one locally, either with or without radiation. Groups treated with combination of local temozolomide, local BCNU and radiation therapy had 75% long-term survivors.

The Company’s BranchPoint device was invented to deliver multiple therapeutics, such as stem cells, chemotherapy or gene therapy vectors, through the radial deployment of a flexible catheter to specific brain target areas through a single brain penetration, and licensed from UCSF (University of California, San Francisco). The current standard of care is the use of straight, rigid needles, often requiring surgeons to penetrate the brain multiple times for delivering therapeutics, which in turn may increase the risk of bleeding, stroke and reflux of therapeutics back out to the brain surface. An animal study at UCSF(3) demonstrated that the use of a straight needle was associated with reflux of at least 75% of the infusion while no reflux was found with the BranchPoint device. The development of the BranchPoint device was originally funded with $1.8 million by California’s Stem Cell Agency CIRM (California Institute of Regenerative Medicine). A 510(k) application was submitted to the FDA in June 2015.

Additional information about the Company may be found on its website, www.accurexa.com.

Notes:

(1) Brem S, Tyler BM, Li K, Pradilla G, Legnani F, Caplan J, et al. Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 2007; 60:643-50.

(2) Renard Recinos V, Tyler BM, Brem H, et al. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery 2010; 66:530-537.

(3) Silvestrini MT, Yin D, Coppes VG, Mann P, Martin AJ, Larson PS, Starr PA, Gupta N, Panter SS, Desai TA, Lim DA. Radially branched deployment for more efficient cell transplantation at the scale of the human brain. Stereotact Funct Neurosurg. 2013;91(2):92-103.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the ability of the Company to successfully develop and commercialize novel neurological therapies based on its BranchPoint device or U.S. Patent No. 8,895,597 B2, or its ACX-31 program and execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

Contact Investor Relations:

David Burke
The Ruth Group
Tel.: 646-536-7009
dburke@theruthgroup.com

Accurexa Inc.
info@accurexa.com
Tel.: 302-709-1822

SOURCE: Accurexa Inc.

ReleaseID: 432229